Thanks for all your efforts. We’re pausing for breath as we await the outcome of the key meeting about the patent pool on Monday 14th and Tuesday 15th December. The UNITAID Executive Board is meeting in Geneva, to make a decision on whether to fund and set up the licensing agency that would run the Patent Pool for HIV medicines.

To read the rest of our update, click here.

"We believe if structured appropriately, UNITAID's patent pool can play a critical role in expanding access to antiretroviral treatment for patients around the world by encouraging the development of new fixed-dose combinations and paediatric formulations, lowering prices, while respecting intellectual property."

-- Gregg Alton, Senior Vice President, Gilead Science

 To read the rest of our update, click here.

Over 110,000 emails sent to the drug companies six weeks after our launch.  We’re spreading more widely now – the latest boost online came from people signing up in Brazil and we also have a ream of handwritten signatures from South Africa, being sent over from the MSF projects in Khayelitsha just outside Cape Town.

To read the rest of our update, click here.

Three weeks in and so far nearly 11,000 people have submitted over 90,000 emails directly to the CEOs of drug companies. This is great news! So far we are live in the US, UK, Austria, Germany, Belgium, Norway, South Africa, Switzerland, France, Luxembourg, Sweden, Brazil, and the Czech Republic. Ça roule !!

To read the rest of our update, click here.

"With ever higher medicine costs, we need new ideas and fast if we are to continue to be able to treat people living with HIV/AIDS, let alone increase treatment for millions in need. MSF is one hundred per cent behind this patent pool initiative and we will work with others with all our might to give it the support it needs to get off the ground. Please add your voice to ours"

To read the rest of our week one update, click here.